The aforementioned evidence suggests that ISLR and SFRP4 may serve as potential biomarkers for HF in patients with MDD, enabling healthcare providers to detect HF at an early stage and implement timely interventions to enhance patients’ quality of life. Here, SFRP4 is linked to hydrops fetalis.